Viridian Therapeutics (VRDN) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 2, 2026, with voting open until June 1, 2026, at 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by May 19, 2026.

• Meeting will be held virtually, allowing remote participation and voting.

Voting matters and shareholder proposals

• Election of two Class II director nominees, Tomas Kiselak and Jennifer K. Moses, to serve until the 2029 annual meeting.

• Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

• Advisory vote to approve named executive officer compensation.

• Advisory vote on the frequency of future say-on-pay votes, with the board recommending an annual vote.

• Provision to transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Board recommends all proposals, including director nominees and auditor ratification.

• Nominees for Class II directors are presented for shareholder election.